Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Ovarian Serous Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Ovarian Cancer (550
)
Ovarian Cancer (550
)
›
Associations
(31)
News
Trials
Search handles
@ChristiKimMD
@DocMCotant
@Dr_R_Kurzrock
@MichalisLiontos
@SidYadavMD
@VivekSubbiah
@cancerassassin1
@weldeiry
Search handles
@ChristiKimMD
@DocMCotant
@Dr_R_Kurzrock
@MichalisLiontos
@SidYadavMD
@VivekSubbiah
@cancerassassin1
@weldeiry
Filter by
Latest
9ms
Great start to the #nrgoncology Summer Symposium on Rare Tumors. Dr. Lauren Grisham highlights active study NRG-GY019 evaluating the use of Letrozole vs chemo in the initial managment of low grade serous ovarian cancer. This study by @amandanfader and colleagues will answer a… https://t.co/8O9szdMKYS (@JCohenMD)
9 months ago
letrozole
9ms
Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/6LPaFtJlGv (@OncLive)
9 months ago
Clinical
|
avutometinib (VS-6766) • defactinib (VS-6063)
10ms
Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/i0gMeFRFqm (@OncLive)
10 months ago
Clinical
|
avutometinib (VS-6766) • defactinib (VS-6063)
10ms
Kicking off presentations, we have Dr. @farhia_kabeer presenting “The evolution of high grade serous ovarian cancer under the pressure of non-cytotoxic and cytotoxic treatment.” Farhia is a Post-Doctoral Fellow under the supervision of Dr. @YvetteDrew and Dr. David Huntsman. (@GCI_Cluster)
10 months ago
10ms
Hear from Dr. @BanerjeeSusana @royalmarsdenNHS, discussing results from the #RAMP201 trial presented at #ASCO23 and their importance in advancing the care of patients with #lowgradeserous #ovariancancer #LGSOC. (@VerastemOncolog)
10 months ago
Clinical
10ms
#LGSOC Low grade serous ovarian cancer. @ASCO #ASCO23 (@CrozrX)
10 months ago
11ms
The results of @GOG 3026 presented at #SGO2023. #Ribociclib & #Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer. From @VuMedi. @kisqali_us #clinicaltrial #ovariancancer #oncology #SGOmtg #gyncsm The GOG Founda…https://t.co/WbDTstiRBI https://t.co/Uu5Vk4A1uJ (@dsmgyo)
11 months ago
Clinical
|
Kisqali (ribociclib) • letrozole
12ms
Kocher’s manoeuvre in a suprarenal lymph node relapse in a Low grade serous ovarian cancer… #anatomy #SCR #ovariancancer #surgery @lchiv4 (@BoriaFelix)
12 months ago
Surgery
1year
Absolutely!! @udai_banerji has really fantastic LGSOC data in FRAME study (both KRAS and WT). Durable responses, good safety profile, low discontinuation rate. Bigger RAMP201 study is recruiting in 🇺🇸 🇨🇦 🇬🇧 🇪🇺 low grade serous ovarian #cancer @FDAOncology https://t.co/5IGM0vZ8pg (@CrozrX)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
1year
Neoadjuvant Olaparib WINDOW Trial in Newly diagnosed BRCA mutant high grade serous ovarian cancer (including RAD51C, PALB2): 53% PR, 46% SD, 0% PD, 1 patient with pathological CR, 85% no gross residual dz, 14% < 1cm residual. #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress (@ChristiKimMD)
1 year ago
Clinical
|
PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C)
|
PALB2 mutation • BRCA mutation • RAD51 mutation
|
Lynparza (olaparib)
1year
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer https://t.co/AVVsziycAe @NatureGenet (@cancerassassin1)
1 year ago
HRD (Homologous Recombination Deficiency)
over1year
Really interesting study! Heaps to unpack there. Perhaps explains why high-grade serous ovarian responds poorly - low TMB, out of control aneuploidy. Any impact of whole-genome doubling? Or protein markers in the microenvironment (PDL1 etc)? (@kylie_gorringe)
over 1 year ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-L
over1year
50% of high-grade serous ovarian tumors will have HRD: 15% germline BRCA1/2 10% somatic BRCA1/2 25% others Important to perform both germline and somatic testing to identify patients who may benefit from PARPi Excellent talk by @theresalwerner @btfoundation (@SidYadavMD)
over 1 year ago
Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
over1year
Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer | Breast Cancer | JAMA Oncology | JAMA Network https://t.co/55Fy7G9jdn (@weldeiry)
over 1 year ago
BRCA1 (Breast cancer 1, early onset)
almost2years
New #CDR article: A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report🌟 https://t.co/ZInFmHMbQT @danecheasley @NadineHempel @ChiappinelliLab @KDRichardson924 @JonesAnnwen @RareOvarCancers (@cdrjournal)
almost 2 years ago
Clinical
|
RAD51C (RAD51 paralog C)
|
RAD51 mutation
almost2years
Congrats @VivekSubbiah for the huge effort that led to the tumour agnostic indication!!!! Major change for rare ovarian histologies as well. We should screen for BRAF mutations Low Grade Serous #ovarian cancer patients. @ESGO_society @HeSMOtweet @ENYGO_official (@MichalisLiontos)
almost 2 years ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
2years
Jam packed tour de force plenary presentation by @AnaOaknin "Pathways beyond BRCA". Strong insights into targeting replicative stress in high-grade serous ovarian cancer. Brilliant & so thought provoking. #ANZGOG2022ASM (@djmarsh24)
2 years ago
BRCA (Breast cancer early onset)
2years
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer | Nature Communications https://t.co/K5GmzG3wCy (@VivekSubbiah)
2 years ago
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
over2years
@EileenMOReilly 65yo ECOG PS 0 w synchronous unresectable 4cm panc head adenoca and Ovarian serous adenoca: mod ascites(pos ov ca), perit nods, left Ov mass; CA125>2600; CA19-9 1400; suspect BRCA mutn as also 3 1st deg relatives affected; germline and NGS pending; frontline tx? (@DocMCotant)
over 2 years ago
Next-generation sequencing
|
BRCA (Breast cancer early onset) • CA 19-9 (Cancer antigen 19-9)
almost3years
I forgot... High-grade serous carcinoma of ovary / fallopian tube / peritoneum is an important differential diagnosis. I'd like to try WT-1 and/or PAX8. (@NeoCrazee)
almost 3 years ago
PAX8 (Paired box 8)
3years
Details matter. Pt fails exp pi3k & MEK inh, trametinib & tamoxifen, & letrozole—but then has super response to trametinib & letrozole: “KRAS-mutated, ER-positive lserous ovarian cancer: Unraveling an exceptional response mystery” Kato KurzrockLab https://t.co/9uwgbGU8PY (@Dr_R_Kurzrock)
3 years ago
KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor)
|
KRAS mutation • ER positive
|
Mekinist (trametinib) • tamoxifen • letrozole
over3years
"#BRCA testing in women with high-grade serous #OvarianCancer: #gynecologic oncologist-initiated testing compared with #genetics referral " 👇👇👇 https://t.co/AecU4ewm32 #GYNonc @IJGCfellows #Cancer #MedTwitter @GynMe4 @gyncsm @pedroramirezMD (@IJGConline)
over 3 years ago
Clinical
|
BRCA (Breast cancer early onset)
over3years
#MolPathMonday @AMPath #AMPath20 Tumor only sequencing is performed on an ovarian serous carcinoma with a tumor content of approximately 50%. A pathogenic BRCA1 variant is identified at a variant allele fraction (VAF) of 25%. How would you report this variant? (@LJTafeMD)
over 3 years ago
BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset)
almost4years
Preliminary results from a small, ongoing phase 1 trial showed that in patients with KRAS-mutant low-grade serous ovarian cancer, the ORR with the the RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib was 67%. @udai_banerji @royalmarsdenNHS https://t.co/1VuezmFvrw (@OncLive)
almost 4 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
avutometinib (VS-6766) • defactinib (VS-6063)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login